DE60224002D1 - Kathepsin Y Inhibitoren für die Entwicklung von Medikamenten zur Schmerzbehandlung - Google Patents

Kathepsin Y Inhibitoren für die Entwicklung von Medikamenten zur Schmerzbehandlung

Info

Publication number
DE60224002D1
DE60224002D1 DE60224002T DE60224002T DE60224002D1 DE 60224002 D1 DE60224002 D1 DE 60224002D1 DE 60224002 T DE60224002 T DE 60224002T DE 60224002 T DE60224002 T DE 60224002T DE 60224002 D1 DE60224002 D1 DE 60224002D1
Authority
DE
Germany
Prior art keywords
cathepsin
development
inhibitors
pain medication
pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60224002T
Other languages
English (en)
Other versions
DE60224002T2 (de
Inventor
Hermann Prof Dr Luebbert
Beate Dr Schmitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biofrontera Bioscience GmbH
Original Assignee
Biofrontera Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biofrontera Pharmaceuticals GmbH filed Critical Biofrontera Pharmaceuticals GmbH
Publication of DE60224002D1 publication Critical patent/DE60224002D1/de
Application granted granted Critical
Publication of DE60224002T2 publication Critical patent/DE60224002T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96466—Cysteine endopeptidases (3.4.22)
DE60224002T 2002-02-14 2002-02-14 Kathepsin Y Inhibitoren für die Entwicklung von Medikamenten zur Schmerzbehandlung Expired - Fee Related DE60224002T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02003400A EP1336847B1 (de) 2002-02-14 2002-02-14 Kathepsin Y Inhibitoren für die Entwicklung von Medikamenten zur Schmerzbehandlung

Publications (2)

Publication Number Publication Date
DE60224002D1 true DE60224002D1 (de) 2008-01-24
DE60224002T2 DE60224002T2 (de) 2008-11-06

Family

ID=27619135

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60224002T Expired - Fee Related DE60224002T2 (de) 2002-02-14 2002-02-14 Kathepsin Y Inhibitoren für die Entwicklung von Medikamenten zur Schmerzbehandlung

Country Status (4)

Country Link
EP (1) EP1336847B1 (de)
AT (1) ATE381017T1 (de)
DE (1) DE60224002T2 (de)
ES (1) ES2296834T3 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004077053A1 (en) * 2003-02-25 2004-09-10 Biofrontera Pharmaceuticals Gmbh Cathepsin y for the treatment of pain
US20070155650A1 (en) * 2003-12-30 2007-07-05 Aventis Pharmaceuticals Inc. Use of cathepsin z inhibitors for the treatment of rhuematoid arthritis and other autoimmune diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0831920A4 (de) * 1995-06-06 2003-03-19 Athena Neurosciences Inc Neues cathepsin sowie verfahren und zusammensetzungen zur inhibierung desselben
AU1926699A (en) * 1997-12-18 1999-07-05 Immunex Corporation Cathepsin dc proteins, dna encoding the proteins, and their use in human cancer prognosis
WO2001023571A1 (en) * 1999-09-30 2001-04-05 The Regents Of The University Of Michigan Methods and compositions relating to sodium channel beta1a subunits

Also Published As

Publication number Publication date
EP1336847B1 (de) 2007-12-12
EP1336847A1 (de) 2003-08-20
ATE381017T1 (de) 2007-12-15
ES2296834T3 (es) 2008-05-01
DE60224002T2 (de) 2008-11-06

Similar Documents

Publication Publication Date Title
DE60311272D1 (de) Neue purin- oder pyrrolol(2,3-d)pyrimidin-2-carbonsäurenitrile zur behandlung von mit cysteinproteaseaktivität assoziierten krankheiten
DE69738581D1 (de) Menschliche dnase i hyperaktive varianten
EP1302542A4 (de) Neues, physiologisch aktives peptid und dessen verwendung
HUP0301246A2 (hu) Humán véralvadási faktor VII változatai
ATE450269T1 (de) Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten
HUP0300299A2 (hu) Szabad aminosavakat tartalmazó kompozíció
BRPI0407139A (pt) Compostos de amida substituìda por tri(ciclo)
BR0316502A (pt) Compostos quìmicos
DE602005013648D1 (de) Behandlung von bakteriellen infektionen
DE602004017202D1 (de) Caseinhydrolysat, verfahren zur dessen herstellung sowie dessen verwendung
ATE370968T1 (de) Varianten des menschliche koagulationsfaktors vii
DE60306505D1 (de) Verfahren zur behandlung von brustdrüsenerkrankungen
HUP0301179A2 (hu) Módosított VIII-as faktor
ATE458057T1 (de) Varianten der faktor-vii- oder -viia-gla-domäne
DE60218843D1 (de) Verfahren zur identifizierung von mitteln zur behandlung von diabetes
ATE395602T1 (de) Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
DE60224002D1 (de) Kathepsin Y Inhibitoren für die Entwicklung von Medikamenten zur Schmerzbehandlung
ATE363923T1 (de) Verwendung von flumazenil zur herstellung eines medikaments für die behandlung von kokainabhängigkeit
DE60216457D1 (de) Carbamate verbindungen zur behandlung oder verhutung von psychotischen krankheiten
ATE166656T1 (de) Humanes galanin, cdna-klone die für humanes galanin kodieren und eine methode humanes galamin herzustellen
ATE353912T1 (de) Peptizusammensetzung für die mundhöhle
NO20052525D0 (no) Spleisevariant av humant hypofyseveksthormon
ATE374593T1 (de) Methode zur haarbehandlung gekennzeichnet durch applikation bestimmter 2-hydroxyalkansäuren
BR0307039A (pt) Compostos, em particular de derivados uréias ou ésteres do ácido haloacetamidobenzóico e sua utilização para o tratamento de doenças parasitárias
DE60120187D1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee